Brief: Ascletis Announces U.S. FDA Clearance Of Ind Application For Its Oral Small Molecule Il-17 Inhibitor, ASC50, For The Treatment Of Psoriasis
22/05/2025 12:08
May 22 (Reuters) - Ascletis Pharma Inc 1672.HK: ASCLETIS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ITS ORAL SMALL MOLECULE IL-17 INHIBITOR, ASC50, FOR THE TREATMENT OF PSORIASIS ASCLETIS PHARMA INC - PHASE I TRIAL DOSING EXPECTED TO START IN Q3 2025 Source text: ID:nPn77l9L0a Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management